Cancer vaccines
Discover how cancer vaccines harness the immune system to recognize and target tumor cells, including key antigen types, vaccine platforms, mechanisms of action, and emerging therapeutic strategies.
Cancer vaccines are immunotherapeutic agents designed to elicit or amplify tumor-specific immune responses by presenting tumor-associated or tumor-specific antigens to the host immune system. They aim to generate durable T cell and, in some cases, antibody-mediated immunity that recognizes and eliminates malignant cells while sparing healthy tissue.
Tumors accumulate genetic and epigenetic alterations that produce aberrant proteins distinguishable from self. These altered proteins, together with re-expressed developmental or tissue-restricted antigens, provide molecular signatures the immune system can, in principle, recognize. Cancer vaccines exploit this antigenic distinction to prime adaptive immunity, converting tumors from immunologically "cold" to "hot" states permissive for cytotoxic clearance.¹
Unlike prophylactic vaccines against infectious agents, most cancer vaccines are therapeutic: they are administered after malignancy is established and must overcome an immunosuppressive tumor microenvironment (TME), central tolerance to self-antigens, and tumor-intrinsic mechanisms of immune escape. A notable exception is prophylactic vaccination against oncogenic viruses such as human papillomavirus (HPV) and hepatitis B virus (HBV), which prevents virally driven malignancies by blocking initial infection.²
What classes of tumor antigens are targeted by cancer vaccines?
The efficacy of a cancer vaccine depends heavily on the nature of the antigen it delivers. Antigen selection determines the breadth of immune recognition, the risk of off-target autoimmunity, and the likelihood of overcoming tolerance mechanisms that suppress responses to self-derived epitopes.
- Tumor-associated antigens (TAAs): Self-proteins overexpressed or aberrantly expressed in tumors (eg HER2, MUC1, MAGE family). Broadly shared across patients but subject to central tolerance.
- Tumor-specific antigens (TSAs) / neoantigens: Peptides derived from somatic mutations unique to tumor cells. Highly immunogenic and largely tolerance-free but typically patient-specific.
- Oncoviral antigens: Foreign viral proteins (eg HPV E6/E7) that are strongly immunogenic and shared across virally driven tumors.
- Cancer-testis antigens: Proteins normally restricted to germline tissues but re-expressed in tumors, offering a favorable specificity profile.³
Mechanism of action
Cancer vaccines function by delivering antigen plus an inflammatory context to professional antigen-presenting cells (APCs), predominantly dendritic cells (DCs). Efficient uptake, processing, and cross-presentation of tumor antigens on major histocompatibility complex (MHC) class I and II molecules are required to prime both CD8+ cytotoxic T lymphocytes (CTLs) and CD4+ helper T cells.⁴
Once activated in draining lymph nodes, antigen-specific T cells clonally expand, acquire effector function, and traffic to the tumor. CTLs recognize peptide–MHC I complexes on malignant cells and induce apoptosis via perforin, granzyme, and Fas/FasL pathways. CD4+ helper responses sustain CTL activity, license DCs through CD40–CD40L interactions, and support memory formation. Effective vaccines therefore couple antigen delivery with adjuvants or innate immune stimuli; for example, Toll-like receptor (TLR) agonists — that mature DCs and provide the co-stimulatory signals required to avoid tolerance induction.⁵
Major vaccine platforms
Different vaccine platforms deliver antigen through distinct biological routes, each shaping the resulting immune response. The choice of platform influences antigen presentation efficiency, the balance of humoral versus cellular immunity, manufacturing feasibility, and adaptability to personalized approaches.
Platform
mRNA platforms have gained particular prominence because they enable rapid design of personalized neoantigen vaccines: tumor sequencing identifies patient-specific mutations, immunogenic epitopes are predicted computationally, and a bespoke mRNA construct is manufactured within weeks.⁶
How do cancer vaccines overcome immune tolerance?
Cancer vaccines overcome tolerance by combining antigen delivery with strong innate immune activation, forcing DC maturation and bypassing the anergic states that normally develop against self-antigens. Adjuvants engaging pattern recognition receptors, prime-boost regimens, and selection of mutation-derived neoantigens all reduce the influence of central and peripheral tolerance mechanisms.
Central tolerance eliminates high-affinity self-reactive T cells during thymic development, leaving a repertoire biased against many TAAs. Neoantigen-based vaccines circumvent this constraint because mutated epitopes were never presented in the thymus and therefore retain a full T cell receptor repertoire. Peripheral tolerance, mediated by regulatory T cells (Tregs), inhibitory checkpoints such as PD-1 and CTLA-4, and immunosuppressive cytokines like TGF-β, is more difficult to overcome, which is why vaccines are frequently combined with checkpoint inhibitors to sustain vaccine-induced T cell activity within the TME.⁷
Why have therapeutic cancer vaccines been historically challenging?
Therapeutic cancer vaccines have shown modest single-agent efficacy because tumors evolve multiple, overlapping mechanisms of immune evasion that blunt vaccine-induced responses. These include downregulation of MHC I, defects in antigen processing, recruitment of suppressive myeloid and regulatory cell populations, and metabolic hostility within the TME.
Tumor heterogeneity further complicates vaccination: antigen loss variants can emerge under immune pressure, allowing resistant clones to expand. Additionally, chronic antigen exposure in advanced disease drives T cell exhaustion, characterized by sustained expression of inhibitory receptors and progressive loss of effector function. Contemporary strategies address these limitations by targeting multiple neoantigens simultaneously, combining vaccines with checkpoint blockade, and administering vaccines in minimal residual disease settings where tumor burden and immunosuppression are lower.⁸
Combination strategies
Because vaccination alone often fails to sustain effector responses within an immunosuppressive TME, cancer vaccines are increasingly deployed in combination regimens. Rational pairings aim to amplify priming, relieve suppression, or expose additional antigens through immunogenic cell death.
- Immune checkpoint inhibitors: Anti–PD-1 and anti–CTLA-4 antibodies preserve vaccine-primed T cells from exhaustion and enhance intratumoral function.
- Cytotoxic therapies: Certain chemotherapies and radiotherapy induce immunogenic cell death, releasing tumor antigens and damage-associated molecular patterns that boost DC activation.
- Cytokine support: Agents such as IL-2 or IL-15 superagonists promote expansion and persistence of vaccine-induced T cells.
- Adoptive cell therapies: Vaccines can boost transferred T cell products in vivo, extending their functional lifespan.⁹
Frequently asked questions
How do prophylactic and therapeutic cancer vaccines differ?
Prophylactic cancer vaccines prevent malignancy by targeting oncogenic pathogens such as HPV or HBV before infection is established, generating protective humoral immunity. Therapeutic vaccines, in contrast, are administered after cancer diagnosis and aim to induce cellular immunity — primarily CTL responses — against tumor antigens present in already-transformed cells.
Why are neoantigen vaccines considered particularly promising?
Neoantigens arise from tumor-specific mutations and are therefore recognized as foreign by the immune system, bypassing central tolerance. This produces higher-affinity T cell responses with reduced autoimmune risk. Advances in tumor sequencing, epitope prediction, and mRNA manufacturing now make personalized neoantigen vaccines clinically feasible within therapeutically relevant timeframes.¹⁰
Do cancer vaccines generate immunological memory?
Yes. Effective vaccines induce memory CD8+ and CD4+ T cell populations capable of long-term surveillance. This memory compartment is particularly important in adjuvant settings, where vaccines are used post-surgery or post-chemotherapy to eliminate residual disease and reduce recurrence risk.
References
- Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
- Finn OJ. The dawn of vaccines for cancer prevention. Nat Rev Immunol. 2018;18(3):183–194.
- Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
- Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24.
- Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360–378.
- Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355–1360.
- Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215–229.
- Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35.
- Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401–3412.
- Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–150.